Last updated: September 8, 2026
Ralinepag is an investigational oral prostacyclin I2 receptor agonist for pulmonary arterial hypertension. Johnson & Johnson’s Phase 3 ADVANCE OUTCOMES study did not meet its primary endpoint, and the company discontinued further development. Ralinepag has no FDA approval, no Orange Book listing, no commercial revenue, and no established launch date. Its current direct market value is therefore effectively zero unless another sponsor resumes development or acquires the program.
What is the current development status of ralinepag?
Ralinepag development has ended under Johnson & Johnson following failure of the pivotal ADVANCE OUTCOMES study.
The study evaluated once-daily oral ralinepag against placebo in patients with pulmonary arterial hypertension receiving background therapy. The primary endpoint was a composite of disease progression or death. Johnson & Johnson reported that the study did not meet this endpoint and announced that it would stop further development of the program. [1]
| Item |
Ralinepag status |
| Active ingredient |
Ralinepag |
| Drug class |
Oral prostacyclin I2 receptor agonist |
| Target disease |
Pulmonary arterial hypertension |
| Sponsor |
Johnson & Johnson / Janssen |
| Lead pivotal study |
ADVANCE OUTCOMES |
| Clinical status |
Phase 3 failure |
| FDA approval |
None |
| FDA filing |
No public NDA approval |
| Orange Book status |
No listed drug product |
| Commercial sales |
None |
| Current launch date |
None |
| Development outlook |
Discontinued by original sponsor |
Ralinepag was intended to compete with selexipag, marketed as Uptravi, while offering oral administration and a differentiated pharmacologic profile within the prostacyclin pathway.
Why did ralinepag fail in Phase 3?
The decisive issue was the failure to demonstrate a statistically significant improvement in the ADVANCE OUTCOMES composite primary endpoint. The study was designed to test whether ralinepag could reduce clinically meaningful PAH progression or death in patients already receiving background therapy.
Earlier development work had generated evidence of improved pulmonary vascular resistance and other hemodynamic measures. Those results did not translate into a successful event-driven morbidity and mortality outcome in the pivotal study. [1]
How did ADVANCE OUTCOMES compare with earlier ralinepag trials?
Earlier studies included dose-ranging, long-term extension, and hemodynamic assessments. These studies supported biological activity, but they were not sufficient to establish clinical benefit for regulatory approval.
| Development phase |
Objective |
Outcome |
| Early Phase 2 studies |
Dose selection and safety |
Supported continued development |
| Hemodynamic studies |
Pulmonary vascular resistance and cardiac function |
Showed pharmacodynamic activity |
| Long-term extension studies |
Durability and safety |
Provided additional exposure data |
| ADVANCE OUTCOMES |
Morbidity and mortality benefit |
Primary endpoint not met |
The result illustrates the commercial and regulatory difference between improving hemodynamics and reducing disease-progression events. PAH therapies must demonstrate a clinically meaningful benefit acceptable to regulators and physicians, particularly when the target population is already receiving combination therapy.
When does ralinepag lose exclusivity?
Ralinepag has no approved-product exclusivity period because it has not received FDA approval. There is no commercial launch date from which regulatory exclusivity would run.
Potential patent protection may continue for specific chemical compounds, formulations, methods of treatment, or manufacturing processes. That protection does not create market exclusivity for an unapproved product and does not establish a commercial value without renewed clinical development.
What patents protect ralinepag?
Publicly available development records identify patent protection around the ralinepag compound and related pharmaceutical technology, but no approved-product patent listing exists in the FDA Orange Book.
The relevant distinction is:
- Compound patents may cover ralinepag or related chemical structures.
- Formulation patents may cover oral dosage forms, release profiles, or excipient combinations.
- Method-of-use patents may cover treatment of PAH or other pulmonary vascular diseases.
- Manufacturing patents may cover synthesis, purification, or solid-state forms.
- Orange Book patents apply only to an approved drug product listed by the FDA.
Because ralinepag has not been approved, there are no Orange Book patent numbers or FDA-listed expiration dates that would define generic entry. A patent owner could still assert non-Orange Book rights against a future developer, but those rights would need to be evaluated claim by claim.
What is the FDA regulatory status of ralinepag?
Ralinepag is not FDA-approved. No public FDA label, approval letter, or Orange Book listing identifies ralinepag as an approved drug.
The failed Phase 3 outcome means Johnson & Johnson did not have a conventional basis for submitting a successful NDA based on the completed pivotal program. Any future approval effort would likely require new clinical evidence, a redesigned development strategy, or a new sponsor willing to accept substantial regulatory risk.
Could ralinepag still reach the market?
A future relaunch is possible in a legal and technical sense but is commercially remote. A new sponsor would likely need to:
- Obtain rights to the compound and supporting data.
- Determine whether existing clinical data can support a new protocol.
- Define a new endpoint strategy accepted by the FDA.
- Conduct additional Phase 2 or Phase 3 studies.
- Resolve patent, manufacturing, formulation, and freedom-to-operate issues.
- Rebuild physician and investor confidence after the pivotal failure.
The most likely development outcome is no commercial launch unless the asset is acquired and repositioned for a narrower population or a different clinical endpoint.
What generic entry risks exist for ralinepag?
There is currently no generic-entry risk because there is no approved ralinepag product. A future generic applicant could not file a conventional abbreviated new drug application against a nonexistent reference-listed drug.
If ralinepag were later approved, entry could involve:
- Paragraph IV challenges to listed patents.
- Patent litigation under the Hatch-Waxman framework.
- Formulation or dosage-form disputes.
- Method-of-use carve-outs.
- 30-month stays triggered by patent litigation.
- Competition from existing PAH therapies before patent expiry.
No publicly established Paragraph IV litigation or settlement agreement has created a defined generic launch date for ralinepag.
What is the Orange Book status of ralinepag?
Ralinepag has no Orange Book status as an approved product. The FDA Orange Book does not provide a reference-listed drug, listed patents, pediatric exclusivity, or generic-approval pathway for ralinepag. [2]
How does ralinepag compare with Uptravi and other PAH drugs?
Ralinepag was positioned most directly against selexipag, the active ingredient in Uptravi. Both are oral prostacyclin-pathway therapies, but only selexipag has established FDA approval and commercial sales.
| Product |
Active ingredient |
Route |
Status |
Commercial position |
| Uptravi |
Selexipag |
Oral and intravenous formulation in some markets |
FDA-approved |
Established PAH product |
| Orenitram |
Treprostinil |
Oral |
FDA-approved |
Oral prostacyclin-pathway competitor |
| Tyvaso |
Treprostinil |
Inhaled |
FDA-approved |
Inhaled PAH therapy |
| Remodulin |
Treprostinil |
Injectable |
FDA-approved |
Parenteral therapy |
| Flolan/Veletri |
Epoprostenol |
Intravenous |
FDA-approved |
Acute and advanced PAH use |
| Ralinepag |
Ralinepag |
Oral |
Development discontinued |
No sales |
Ralinepag’s intended commercial advantages were oral delivery, receptor selectivity, and potential use in combination treatment. Those advantages were not enough to overcome the failed Phase 3 outcome.
Which companies are challenging ralinepag?
No company has a public generic or biosimilar challenge against ralinepag. The product is not approved, and there is no listed reference product against which an ANDA applicant could file.
The competitive threat comes from established therapies rather than direct patent challengers. Relevant competitors include Johnson & Johnson’s own Uptravi franchise, United Therapeutics’ treprostinil products, Bayer’s Adempas, and combination regimens using endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin therapies.
What is the market projection for ralinepag?
Ralinepag’s current revenue projection is zero because the program has no approval, no launch plan, and no active commercial supply.
A successful late-stage PAH launch could theoretically have produced a substantial specialty-pharmaceutical franchise. Uptravi demonstrates the revenue potential of an oral prostacyclin-pathway product, with annual sales in the billion-dollar range for Johnson & Johnson in recent years. [3] Ralinepag, however, cannot be valued on that benchmark without a viable development program.
Ralinepag market scenarios
| Scenario |
Probability-weighted commercial interpretation |
| No further development |
Revenue remains zero |
| Asset sale and clinical restart |
Multi-year development period with high regulatory risk |
| Approval after successful redevelopment |
Potential specialty PAH revenue, but no reliable launch estimate |
| Narrow-label approval |
Lower commercial ceiling but potentially more focused clinical positioning |
| Acquisition by a PAH specialist |
Could preserve the asset, but would require new capital and trial execution |
A theoretical post-approval peak-sales range cannot be treated as a current forecast. The product lacks the regulatory and clinical foundation required for a defensible revenue model.
How strong is the ralinepag patent estate?
The patent estate has limited practical value in its current state. Patent duration may extend beyond the point of the Phase 3 failure, but patents do not compensate for the absence of regulatory approval.
Patent strength should be assessed across four categories:
- Compound claims: potentially the most valuable claims if valid and broad.
- Formulation claims: relevant if the oral product has a difficult-to-reproduce dosage form or release profile.
- Method-of-use claims: potentially useful for specific PAH populations but vulnerable to design-around and label carve-out strategies.
- Manufacturing claims: potentially important if synthesis or purification is technically difficult.
The economic strength of each category depends on claim scope, validity, remaining term, prosecution history, ownership chain, and whether an approved product ever emerges. No Orange Book listing currently converts this patent position into a defined market barrier.
What manufacturing and intellectual-property barriers affect ralinepag?
A future developer would face several technical barriers:
- Re-establishing a scalable, reproducible active pharmaceutical ingredient process.
- Demonstrating control of impurities and polymorphic forms.
- Confirming stability of the selected oral formulation.
- Rebuilding commercial manufacturing capacity after program discontinuation.
- Confirming assignment and licensing rights across historical developers.
- Managing freedom-to-operate risk around prostacyclin receptor agonists.
- Generating new clinical data despite the failed pivotal endpoint.
These barriers increase the cost and timeline of any restart. They also reduce the likelihood that a generic or specialty company would pursue the asset without discounted acquisition terms.
What licensing deals involve ralinepag?
Ralinepag originated through the Actelion and Johnson & Johnson development network. Johnson & Johnson obtained the Actelion business, including its PAH pipeline and marketed products, in 2017. The company subsequently developed ralinepag through Janssen. [4]
No active licensing transaction has publicly established a new sponsor, relaunch plan, or commercial partner following the ADVANCE OUTCOMES failure. The absence of a disclosed successor sponsor leaves ownership and future development strategy with the current rights holder unless a later transaction is announced.
What litigation or settlement agreements affect ralinepag?
No major public Hatch-Waxman litigation, Paragraph IV settlement, or biosimilar dispute has established a market-entry timetable for ralinepag.
Biosimilar risk is also not applicable. Ralinepag is a small-molecule drug candidate, not a biologic. If approved in the future, generic rather than biosimilar competition would be the relevant framework.
Key Takeaways
- Ralinepag is an investigational oral prostacyclin I2 receptor agonist for PAH.
- Johnson & Johnson discontinued development after the Phase 3 ADVANCE OUTCOMES study failed its primary endpoint.
- Ralinepag has no FDA approval, Orange Book listing, regulatory exclusivity, commercial revenue, or launch date.
- No Paragraph IV challenge, generic filing, biosimilar dispute, or settlement agreement establishes an entry timetable.
- Patent rights may remain relevant to a future acquirer, but they have limited current economic value without a viable clinical program.
- Current direct market revenue is effectively zero.
- A relaunch would require new sponsorship, substantial additional clinical investment, and a revised regulatory strategy.
FAQs
Is ralinepag the same as Uptravi?
No. Ralinepag and Uptravi are different oral prostacyclin-pathway drugs. Uptravi contains selexipag and is FDA-approved. Ralinepag contains ralinepag and remains unapproved.
Did ralinepag receive FDA breakthrough therapy designation?
There is no public FDA approval record or commercial regulatory milestone establishing a breakthrough therapy approval for ralinepag. The pivotal program failed before approval.
Can a generic company launch ralinepag now?
No. There is no FDA-approved reference-listed ralinepag product. A generic company cannot rely on a conventional ANDA pathway until a reference product exists.
Is ralinepag a biologic with biosimilar competition?
No. Ralinepag is a small-molecule drug candidate. Any future competition would primarily involve generic-drug rules, not the biosimilar pathway.
What would make ralinepag commercially viable again?
A viable restart would require a rights transaction, a credible new clinical strategy, additional evidence of patient benefit, regulatory alignment, and sufficient patent term to support investment. None of those conditions currently produces a defined launch forecast.
References
-
Johnson & Johnson. (2024). Ralinepag Phase 3 ADVANCE OUTCOMES study results. Johnson & Johnson investor and corporate communications.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Johnson & Johnson. (2024). Annual report 2023. Johnson & Johnson.
-
Johnson & Johnson. (2017). Johnson & Johnson completes acquisition of Actelion. Johnson & Johnson corporate communications.